Department of Intensive Care Medicine, Nepean Hospital, Sydney Medical School, Penrith, NSW 2750, Australia.
Ann Intensive Care. 2012 Mar 7;2:8. doi: 10.1186/2110-5820-2-8.
Cardiac biomarkers (CB) were first developed for assisting the diagnosis of cardiac events, especially acute myocardial infarction. The discoveries of other CB, the better understanding of cardiac disease process and the advancement in detection technology has pushed the applications of CB beyond the 'diagnosis' boundary. Not only the measurements of CB are more sensitive, the applications have now covered staging of cardiac disease, timing of cardiac events and prognostication. Further, CB have made their way to the intensive care setting where their uses are not just confined to cardiac related areas. With the better understanding of the CB properties, CB can now help detecting various acute processes such as pulmonary embolism, sepsis-related myocardial depression, acute heart failure, renal failure and acute lung injury. This article discusses the properties and the uses of common CB, with special reference to the intensive care setting. The potential utility of "multimarkers" approach and microRNA as the future CB are also briefly discussed.
心脏生物标志物（CB）最初是为协助心脏事件的诊断而开发的，尤其是急性心肌梗死。其他 CB 的发现、对心脏疾病过程的更好理解以及检测技术的进步，已经推动了 CB 的应用超越了“诊断”的界限。不仅 CB 的测量更加敏感，应用范围现在还涵盖了心脏疾病的分期、心脏事件的时间和预后。此外，CB 已经进入重症监护病房，其应用不仅局限于心脏相关领域。随着对 CB 特性的更好理解，CB 现在可以帮助检测各种急性疾病，如肺栓塞、脓毒症相关心肌抑制、急性心力衰竭、肾衰竭和急性肺损伤。本文讨论了常见 CB 的特性和用途，特别提到了重症监护病房的情况。还简要讨论了“多标志物”方法和 microRNA 作为未来 CB 的潜在用途。
